@WingchiHunt

Researcher @MDAndersonNews focused on AML immunotherapies | Former paed hem/onc 🇳🇿 | Alum @CAGTHouston | Doodler for #DrKittyMDPhD

 Houston, TX
Joined December 2015
  • Tweets221
  • Following252
  • Followers5
11Media
The journey of CAR T-cell cancer research at @Penn @PennMedicine thedp.com/article/2026/08/pe…

The journey of CAR T-cell cancer research at Penn

A look into how renowned Penn immunologist Carl June pioneered CAR T-cell therapies to revolutionize cancer treatment.

thedp.com
1
10
36
1,918
Wingchi Hunt retweeted
Cancer Cell@Cancer_CellSep 17
Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies dlvr.it/TVWvTK
1
24
1
71
6,232
Wingchi Hunt retweeted
Cancer Cell@Cancer_CellSep 15
Latent tumor killers awakened dlvr.it/TVVLMq
1
12
40
4,325
Wingchi Hunt retweeted
Waggoner Lab@LabWaggonerSep 4
Liver-derived β-hydroxybutyrate-CREM signaling axis drives CD8+ T cell immunosenescence @Cell_Metabolism cell.com/cell-metabolism/ful…
4
11
915
Wingchi Hunt retweeted
Paul G Thomas@PGTimmuneSep 3
TCR specificity prediction is advancing rapidly. The central question is not only which TCR sequence recognizes an antigen, but also which TCR pairings make recognition possible & where is the binding boundary? Our new paper tackles this question. 🧵 science.org/doi/10.1126/scie…

Uneven TCR chain pairing constraints govern epitope recognition

Combinatorial pairing of independently recombined T cell receptor (TCR) α- and β-chains is central to diversifying the TCR repertoire. Although sequence motifs in one chain correlate with epitope...

science.org
3
58
3
196
22,097
Can dual-epitope targeting overcome antigen escape in #AML? This study shows anti-LILRB4 STAR-T cells achieved promising #AntiLeukemic activity with a manageable safety profile in relapsed or refractory disease. @MedTsinghua @PKU1898 #STTT #OpenAccess: doi.org/10.1038/s41392-026-0…
Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia

ALT Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia

3
2
780
New online! Towards liquid biopsy-based analysis of antitumour immunity dlvr.it/TThHw9

Towards liquid biopsy-based analysis of antitumour immunity

Nature Reviews Clinical Oncology - Advances in multimodal analyses of diverse cell types and cellular products present in the blood have presented opportunities to non-invasively and repeatedly...

nature.com
7
17
2,275
Capturing and Tracking Clonal T-cell Response to Cancer Neoantigens brnw.ch/21x36aN @ChudakovM @antigenomics
11
26
1,851
Wingchi Hunt retweeted
Klebanoff_Lab@KlebanoffLabJun 1
🚨3rd paper in our PI3Ka public neoantigen trilogy is out in @PNASNews! We show that HLA micropolymorphisms govern whether a neoantigen is visible to T cells by tuning neopeptide dynamics, not presentation or static structure. @MSKCancerCenter @parkerici pnas.org/doi/10.1073/pnas.26…

HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor...

T cell receptor (TCR) restriction by highly polymorphic major histocompatibility complex (MHC) proteins is a foundation of cellular immunity. Altho...

pnas.org
16
1
80
7,269
Excited to present the first pre-print from our group, an investigation the human bone marrow microenvironments in patients with myelodysplastic syndromes (MDS) and normal age-matched subjects using Xenium genotype-informed spatial transcriptomics: biorxiv.org/content/10.64898…
6
38
4
142
13,197
Wingchi Hunt retweeted
Klebanoff_Lab@KlebanoffLabMar 26
🚨Today in @Cancer_Cell: 50,000 tumor genomes via MSK-IMPACT. We map which HLA alleles are highest yield for antigen discovery—and define when HLA LOH constrains targetability. A framework for scaling TCR therapies. @MSKCancerCenter @parkerici authors.elsevier.com/sd/arti…
3
48
197
12,325
🚨NEW consensus doc published "Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles" Cell therapies transformed blood cancers, but solid tumors are a different engineering and delivery problem. This @ASTCT @sitcancer white paper from the 2025 Summit lays out what has to be considered: antigen heterogeneity and on-target, off-tumor risk; hostile tumor microenvironments; limited trafficking and persistence; and practical realities like tissue access and far larger patient populations. Operational plan: standardization, prospective and retrospective sample banking, earlier payer engagement, and regulatory recalibration that is driven by data. #celltherapy #genetherapy #immunotherapy #cancer sciencedirect.com/science/ar…
1
5
13
1,485
🚨NEW - Overcoming functional and translational challenges of cellular immunotherapies for solid tumors in @Cancer_Cell a magnum opus review led by @khalidshahs Yi-Ching Chen, Kok-Siong Chen sciencedirect.com/science/ar…
2
8
1
53
4,512
Wingchi Hunt retweeted
Chris Mason
@mason_lab11 Dec 2025
"Rapid epigenomic classification of acute leukemia" nature.com/articles/s41588-0… Cool new method with @nanopore profiling for rapid combined genetic and epigenetic clinical utility

Rapid epigenomic classification of acute leukemia

Nature Genetics - The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.

nature.com
2
27
137
14,194
#REVIEW 🚨 Tumor heterogeneity shapes progression and treatment, yet bulk expression data fails to capture this. Now Dai et al. outline deconvolution methods that resolve cell-type-specific signals to maximize bulk transcriptomic data. bit.ly/490J71N

A guide to transcriptomic deconvolution in cancer

Nature Reviews Cancer - Tumour heterogeneity has a substantial impact on tumour progression and treatment response, yet bulk expression data obtained from clinical tumour samples obscure this...

nature.com
3
28
1
98
8,291
2025: research in review go.nature.com/4oCK84L
4
113
8
420
51,653
Wingchi Hunt retweeted
Eric Topol
@EricTopol18 Nov 2025
Engineering T cells (CAR-T) has had marked benefits for cancer and autoimmune disease. But doing that inside the patient's body (in vivo) would make that far more practical and less expensive. cell.com/cell-reports-medici…
10
150
9
524
42,015
Stimulation of KitT with 5mM caffeine-kine. #DrKittyMDPhD #Immunology #PhDlife
2
154
PD-1/PD-L1 induced KitT exhaustion #DrKittyMDPhD #Immunology #AcademicTwitter
1
3
272
Wingchi Hunt retweeted
Pavan Bachireddy@pbachi20 Oct 2025
Thrilled to share our 1st preprint (!) on @biorxiv “Molecular and cellular dynamics of measurable residual disease (#MRD) progression in myelodysplastic syndromes (MDS).” Led by the indefatigable Yu-Hsiang Chen in the lab (xitter.cf/PhRMAfoundation/status…). 👉👉biorxiv.org/content/10.1101/…
PhRMA Foundation@PhRMAfoundation2 Oct 2025
#PhF25 awardee Yu-Hsiang Chen, a postdoc @MDAndersonNews, is using single-cell technology to study #cancer cells that remain after stem cell transplant. Understanding these cells could help develop better treatments. @pbachi Watch the full interview: phrmafoundation.org/news-eve…
2
15
4
28
8,824
Load more